X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janssen.
Lead Product(s): Aprocitentan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-132577
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Idorsia Pharmaceuticals
Deal Size: $343.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 05, 2023
Details:
Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Lava Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2023
Details:
Through the collaboration, Janssen enhances its portfolio in B-cell malignancies and strengthens its legacy in hematology, by including C-CAR039 (prizloncabtagene autoleucel), a novel bispecific CAR-T therapy targeting both CD19 and CD20 antigens for the treatment R/R DLBCL.
Lead Product(s): Prizloncabtagene Autoleucel
Therapeutic Area: Oncology Product Name: C-CAR039
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Cellular Biomedicine Group
Deal Size: $245.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 02, 2023
Details:
ESSA will conduct a Phase 1 trial evaluating the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of EPI-7386 when administered in combination with either apalutamide or abiraterone acetate plus prednisone in patients with prostate cancer.
Lead Product(s): Masofaniten,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Essa Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 12, 2023
Details:
The disappointed outcome of the confirmatory trials leads to voluntarily withdraw, in the U.S., accelerated IMBRUVICA® (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma who have received at least one prior therapy and with marginal zone lymphoma.
Lead Product(s): Ibrutinib,Bendamustine
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
Janssen will use Biocytogen’s proprietary RenLite® platform to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Biocytogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 08, 2023
Details:
JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Lead Product(s): PN-235
Therapeutic Area: Dermatology Product Name: JNJ-2113
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Protagonist Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
Lead Product(s): Aprocitentan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-132577
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Idorsia Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Genmab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
